Avizorex Pharma, S.L.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avizorex Pharma, S.L.
Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
- Other Names / Subsidiaries
- AVX Pharma
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.